ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response.
- Published In:
- Journal for immunotherapy of cancer, 10(2) (2022)
- Authors:
- Sousa, Luana Guimaraes de, Rajapakshe, Kimal, Rodriguez Canales, Jaime, Chin, Renee L, Feng, Lei, Wang, Qi, Barrese, Tomas Z, Massarelli, Erminia, William, William, Johnson, Faye M, Ferrarotto, Renata, Wistuba, Ignacio, Coarfa, Cristian, Lee, Jack, Wang, Jing, Melief, Cornelis J M, Curran, Michael A, Glisson, Bonnie S
- Database ID:
- RPEP-06511
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06511APA
Sousa, Luana Guimaraes de; Rajapakshe, Kimal; Rodriguez Canales, Jaime; Chin, Renee L; Feng, Lei; Wang, Qi; Barrese, Tomas Z; Massarelli, Erminia; William, William; Johnson, Faye M; Ferrarotto, Renata; Wistuba, Ignacio; Coarfa, Cristian; Lee, Jack; Wang, Jing; Melief, Cornelis J M; Curran, Michael A; Glisson, Bonnie S. (2022). ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response.. Journal for immunotherapy of cancer, 10(2). https://doi.org/10.1136/jitc-2021-004232
MLA
Sousa, Luana Guimaraes de, et al. "ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response.." Journal for immunotherapy of cancer, 2022. https://doi.org/10.1136/jitc-2021-004232
RethinkPeptides
RethinkPeptides Research Database. "ISA101 and nivolumab for HPV-16+ cancer: updated clinical ef..." RPEP-06511. Retrieved from https://rethinkpeptides.com/research/sousa-2022-isa101-and-nivolumab-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.